Development of a rapid and practical mutation screening assay for human lung adenocarcinoma

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 1900-1906

  Choi, Helen ^a,b   Kratz, Johannes ^a   Pham, Patrick ^a   Lee, Sharon ^a   Ray, Roshni ^a   Kwon, Yong Won ^c   Mao, Jian Hua ^c   Kang, Hio Chung ^b   Jablons, David ^a,b   Kim, Il Jin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Assay; Lung cancer; Mutation

Indexed keywords

B RAF KINASE; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN P53;

ARTICLE; ASIAN; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SMOKING;

ADENOCARCINOMA; AGED; BASE SEQUENCE; BETA CATENIN; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; FRAMESHIFT MUTATION; GENETIC ASSOCIATION STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; MUTATION, MISSENSE; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84861785120     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1396     Document Type: Article

References (20)

1. Edwards BK, Ward E, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116: 544-573, 2010.
2. Dahabreh IJ, Linardou H, Siannis F, et al: Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 16: 291-303, 2010.
3. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909, 2005.
4. Shigematsu H, Lin L, Takahashi T, et al: Clinincal and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005. (Pubitemid 40425952)
5. Riely GJ, Marks J and Pao W: KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201-205, 2009.
6. Marks JL, Broderick S, Zhou Q, et al: Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3: 111-116, 2008. (Pubitemid 351323183)
7. Petitjean A, Mathe E, Kato S, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629, 2007. (Pubitemid 46744292)
8. Kosaka T, Yatabe Y, Onozato R, et al: Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4: 22-29, 2009.
9. Mounawar M, Mukeria A, Le Calvez F, et al: Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 67: 5667-5672, 2007. (Pubitemid 46984998)
10. Jin G, Kim MJ, Jeon HS, et al: PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69: 279-283, 2010.
11. Suzuki Y, Orita M, Shiraishi M, et al: Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 5: 1037-1043, 1990.
12. Milbury CA, Li J and Makrigiorgos GM: PCR-based methods for the enrichment of minority alleles and mutations. Clin Chem 55: 632-640, 2009.
13. Pleasance ED, Stephens PJ, O'Meara S, et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184-190, 2010.
14. Lee W, Jiang Z, Liu J, et al: The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 27: 473-477, 2010.
15. Meyerson M, Gabriel S and Getz G: Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11: 685-696, 2010.
16. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002. (Pubitemid 34716871)
17. Pham D, Kris MG, Riely GJ, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24: 1700-1704, 2006. (Pubitemid 46622141)
18. Lee YJ, Cho BC, Jee SH, et al: Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 28: 487-492, 2010.
19. Conway K, Edmiston SN, Cui L, et al: Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res 62: 1987-1995, 2002. (Pubitemid 34408442)
20. Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180, 2011.